"Clinical Trials"

During the past decade, START Midwest conducted 75 clinical trials. In the 10-year time frame, 75 clinical trials started and 3 clinical trials were completed, i.e. on average, 4% percent of trials that started reached the finish line to date. In the past 5 years, 50 clinical trials started and 3 clinical trials were completed. i.e. 6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "START Midwest" #1 sponsor was "Pfizer" with 6 trials, followed by "Gilead Sciences" with 5 trials sponsored, "Ascentage Pharma Group Inc." with 3 trials sponsored, "Compugen Ltd" with 3 trials sponsored and "Mersana Therapeutics" with 3 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 48 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "START Midwest" #1 collaborator was "Merck Sharp & Dohme LLC" with 6 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator, "Eli Lilly and Company" with 2 trials as a collaborator, "IQVIA Biotech" with 2 trials as a collaborator and "ADIR, a Servier Group company" with 1 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "START Midwest" are "Solid Tumor" (14 trials), "Ovarian Cancer" (13 trials), "Breast Cancer" (11 trials), "Non Small Cell Lung Cancer" (10 trials) and "Advanced Cancer" (8 trials). Many other conditions were trialed in "START Midwest" in a lesser frequency.

Most popular intervention types in "START Midwest" are "Drug" (68 trials), "Biological" (13 trials) and "Combination Product" (2 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (8 trials), "Docetaxel" (3 trials), "Fulvestrant" (3 trials), "Carboplatin" (2 trials) and "Gemcitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "START Midwest" are 72 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "START Midwest". undefined are not yet recruiting, 38 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in START Midwest, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in START Midwest, 75 "Phase 1" clinical trials were conducted, 24 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".